Compare Capital One Financial Corp. (COF) vs Moderna, Inc. (MRNA) Price & Performance

Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.

The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.